T1 直肠癌非根治性内窥镜切除术后的处理方法

IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Best Practice & Research Clinical Gastroenterology Pub Date : 2024-02-01 DOI:10.1016/j.bpg.2024.101895
Hao Dang, Daan A. Verhoeven, Jurjen J. Boonstra, Monique E. van Leerdam
{"title":"T1 直肠癌非根治性内窥镜切除术后的处理方法","authors":"Hao Dang,&nbsp;Daan A. Verhoeven,&nbsp;Jurjen J. Boonstra,&nbsp;Monique E. van Leerdam","doi":"10.1016/j.bpg.2024.101895","DOIUrl":null,"url":null,"abstract":"<div><p>Since the introduction of population-based screening, increasing numbers of T1 rectal cancers are detected and removed by local endoscopic resection. Patients can be cured with endoscopic resection alone, but there is a possibility of residual tumor cells remaining after the initial resection. These can be located intraluminally at the resection site or extraluminally in the form of (lymph node) metastases. To decrease the risk of residual cells progressing towards more advanced disease, additional treatment is usually needed. However, with the currently available risk stratification models, it remains challenging to determine who should and should not be further treated after non-curative endoscopic resection. In this review, the different management strategies for patients with non-curatively treated T1 rectal cancers are discussed, along with the available evidence for each strategy and relevant considerations for clinical decision making. Furthermore, we provide practical guidance on the management and surveillance following non-curative endoscopic resection of T1 rectal cancer.</p></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"68 ","pages":"Article 101895"},"PeriodicalIF":3.2000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521691824000143/pdfft?md5=db68317b9ccbdd8d245b0694536ea500&pid=1-s2.0-S1521691824000143-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Management after non-curative endoscopic resection of T1 rectal cancer\",\"authors\":\"Hao Dang,&nbsp;Daan A. Verhoeven,&nbsp;Jurjen J. Boonstra,&nbsp;Monique E. van Leerdam\",\"doi\":\"10.1016/j.bpg.2024.101895\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Since the introduction of population-based screening, increasing numbers of T1 rectal cancers are detected and removed by local endoscopic resection. Patients can be cured with endoscopic resection alone, but there is a possibility of residual tumor cells remaining after the initial resection. These can be located intraluminally at the resection site or extraluminally in the form of (lymph node) metastases. To decrease the risk of residual cells progressing towards more advanced disease, additional treatment is usually needed. However, with the currently available risk stratification models, it remains challenging to determine who should and should not be further treated after non-curative endoscopic resection. In this review, the different management strategies for patients with non-curatively treated T1 rectal cancers are discussed, along with the available evidence for each strategy and relevant considerations for clinical decision making. Furthermore, we provide practical guidance on the management and surveillance following non-curative endoscopic resection of T1 rectal cancer.</p></div>\",\"PeriodicalId\":56031,\"journal\":{\"name\":\"Best Practice & Research Clinical Gastroenterology\",\"volume\":\"68 \",\"pages\":\"Article 101895\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1521691824000143/pdfft?md5=db68317b9ccbdd8d245b0694536ea500&pid=1-s2.0-S1521691824000143-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best Practice & Research Clinical Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521691824000143\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521691824000143","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

自开展人群筛查以来,越来越多的 T1 直肠癌被发现并通过局部内镜切除术切除。仅靠内镜切除术就能治愈患者,但初次切除后仍有可能残留肿瘤细胞。这些残留细胞可能位于切除部位的腔内,也可能以(淋巴结)转移的形式存在于腔外。为了降低残留细胞向更晚期疾病发展的风险,通常需要进行额外的治疗。然而,就目前可用的风险分层模型而言,确定非根治性内镜切除术后哪些患者应该或不应该接受进一步治疗仍具有挑战性。在这篇综述中,我们讨论了未经根治性治疗的 T1 直肠癌患者的不同治疗策略,以及每种策略的现有证据和临床决策的相关注意事项。此外,我们还为 T1 直肠癌非根治性内镜切除术后的管理和监测提供了实用指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Management after non-curative endoscopic resection of T1 rectal cancer

Since the introduction of population-based screening, increasing numbers of T1 rectal cancers are detected and removed by local endoscopic resection. Patients can be cured with endoscopic resection alone, but there is a possibility of residual tumor cells remaining after the initial resection. These can be located intraluminally at the resection site or extraluminally in the form of (lymph node) metastases. To decrease the risk of residual cells progressing towards more advanced disease, additional treatment is usually needed. However, with the currently available risk stratification models, it remains challenging to determine who should and should not be further treated after non-curative endoscopic resection. In this review, the different management strategies for patients with non-curatively treated T1 rectal cancers are discussed, along with the available evidence for each strategy and relevant considerations for clinical decision making. Furthermore, we provide practical guidance on the management and surveillance following non-curative endoscopic resection of T1 rectal cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.50
自引率
0.00%
发文量
23
审稿时长
69 days
期刊介绍: Each topic-based issue of Best Practice & Research Clinical Gastroenterology will provide a comprehensive review of current clinical practice and thinking within the specialty of gastroenterology.
期刊最新文献
The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy Gut microbiota in colorectal cancer: From pathogenesis to clinic Editorial Board Table of Contents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1